According to Straits Research, the global Plasma Fractionation Market was valued at USD 30.90 billion in 2023 and is projected to grow from USD 33.43 billion in 2024 to USD 68.55 billion by 2032, expanding at a CAGR of 8.2% during the forecast period (2024-2032). This robust growth is driven by the increasing prevalence of immunodeficiency disorders, advancements in plasma-derived therapies, and rising demand for albumin, immunoglobulins, and coagulation factors.
For a detailed understanding, get a full PDF sample copy of the report @ https://straitsresearch.com/report/plasma-fractionation-market/request-sample
Plasma Fractionation Market Catalysts for Expansion
The plasma fractionation market is experiencing accelerated growth due to key factors such as:
Rising Demand for Plasma-Derived Therapies: The growing number of patients requiring immunoglobulins for immune disorders and coagulation factors for hemophilia treatment is significantly propelling market demand.
Advancements in Fractionation Techniques: Innovations in chromatographic techniques and depth filtration are enhancing the efficiency and yield of plasma fractionation.
Expanding Healthcare Infrastructure: Increasing investments in healthcare facilities, particularly in emerging economies, are supporting market expansion.
Government and Private Sector Support: Regulatory approvals and financial backing for research on plasma-derived therapeutics are facilitating growth in this industry.
Plasma Fractionation Market Segment Breakdown
By Product:
Albumin
Immunoglobulins
Intravenous immunoglobulins
Subcutaneous immunoglobulins
Others
Coagulation Factors
Factor VIII
Factor IX
Von Willebrand Factor
Prothrombin Complex Concentrates
Fibrinogen Concentrates
Others
Protease Inhibitors
Others
By Method:
Centrifugation
Depth Filtration
Chromatography
Others
By Application:
Neurology
Hematology
Oncology
Immunology
Pulmonology
Others
By End Use:
Hospitals & Clinics
Clinical Research
Others
Access detailed segmentation @ https://straitsresearch.com/report/plasma-fractionation-market/segmentation
Top Performing Companies in the Plasma Fractionation Market
Several leading companies are driving the plasma fractionation industry with their extensive research, product innovations, and strategic partnerships. The key market players include:
Grifols S.A.
CSL Limited
Takeda Pharmaceutical Company Limited
Octapharma AG
Kedrion S.p.A
LFB S.A.
Biotest AG
Sanquin
Bio Products Laboratory Ltd.
Intas Pharmaceuticals Ltd.
ADMA Biologics
China Biologic Products Holdings Inc.
GC Pharma
Hualan Bioengineering Co., Ltd.
For more information, queries, or customization before buying, visit @ https://straitsresearch.com/buy-now/plasma-fractionation-market
Plasma Fractionation Market Emerging Prospects
The plasma fractionation market presents significant opportunities for expansion, including:
Development of Recombinant Plasma Products: Advances in biotechnology are leading to the production of recombinant coagulation factors, reducing dependency on human plasma.
Expansion in Emerging Markets: Asia-Pacific and Latin America are becoming key markets due to increasing healthcare spending and improved access to plasma-derived therapies.
Rising Awareness and Diagnostic Improvements: Early diagnosis of immunodeficiency disorders and hemophilia is increasing the demand for plasma-based treatments.
Plasma Fractionation Market Industry Movements
Strategic Mergers & Acquisitions: Companies are engaging in collaborations to expand their production capabilities and strengthen their market presence.
Regulatory Approvals & Innovations: New product approvals by regulatory bodies such as the FDA and EMA are further driving market growth.
Increased Investment in R&D: The focus on research and development is leading to novel plasma fractionation techniques and improved product formulations.
Plasma Fractionation Market Geographic Analysis
North America: Dominates the global market due to a strong presence of leading industry players and advanced healthcare infrastructure.
Europe: Witnessing growth due to increasing government initiatives and funding for plasma-derived therapies.
Asia-Pacific: Expected to register the fastest growth, driven by rising investments in healthcare and an increasing patient population.
Latin America & Middle East: Emerging as promising markets due to improving access to medical facilities and regulatory advancements.
Plasma Fractionation Market Data Insights
The market is anticipated to experience steady expansion, with increasing applications of plasma-derived therapies in treating rare and chronic diseases. Investments in R&D and technological advancements will continue to shape the market landscape.
For comprehensive insights and future projections, access the full Plasma Fractionation Market Report by Straits Research today.
